Scientists ‘Delete’ HIV Virus From Human DNA for the First Time

Perhaps most impressive, GlaxoSmithKline, the pharmaceutical company that worked on this vaccine for 30 years, and received $200 million from the Gates Foundation, is making RTS,S available as a nonprofit drug. It will be offered at a low cost to cover manufacturing costs plus a 5% markup, with all that money going back into further research for a malaria vaccine that could be even more effective. The pharmaceutical company has invested more than $365 million to date and expects to invest a further $200 to $250 million until the vaccine is ready for market.